Metastatic Tumor Cell Trap Device in Patients With Advanced Ovarian Cancer

NACompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

March 9, 2017

Primary Completion Date

September 12, 2018

Study Completion Date

December 31, 2019

Conditions
Ovarian Cancer Stage IIICOvarian Cancer Stage IV
Interventions
DEVICE

M-Trap

Device(s) will be surgically implanted in the peritoneal cavity. Up to three (3) M-Trap devices will be surgically implanted via laparotomy in the right and left paracolic (pelvic) gutters and behind segment 6 of the liver within the peritoneal cavity of the patient at the time of surgical resection. Patients will receive standard platinum-based chemotherapy. If the cancer is diagnosed to have recurred, M-Trap devices with captured tumor cells will be removed via minimally invasive surgery (laparoscopy).

Trial Locations (8)

12004

Castellon University General Hospital, Castelló

15706

Complexo Hospitalario Universitario de Santiago, Santiago de Compostela

28033

MD Anderson Cancer Center, Madrid

28046

Hospital La Paz Madrid, Madrid

46014

Valencia-Hospital General, Valencia

46026

Hospital Universitrio y Politècnico La Fe, Valencia

08035

Hospital Universitari Vall d'Hebron, Barcelona

08036

Hospital Clinic de Barcelona, Barcelona

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

MedPass International

INDUSTRY

lead

MTrap, Inc.

INDUSTRY